Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung CancerMotoko Tachihara, Koichi Azuma, Haruko Daga et al.|JAMA Oncology|2023Cited by 68
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)Takashi Seto, Kazuhiko Nakagawa, Kaname Nosaki et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 50
Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trialYoshihiko Maehara, Mototsugu Shimokawa, Ken Shirabe et al.|Surgery Today|2017Cited by 33
Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L)Motoko Tachihara, Kazuhiko Nakagawa, Kayoko Tsujino et al.|Cancer Management and Research|2021Cited by 8
LBA55 WJOG @Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 expressionTakashi Seto, Kazuhiko Nakagawa, Kaname Nosaki et al.|Annals of Oncology|2020Cited by 7